Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws.
(Studio: Aaron Brown) Report introduced.
(Studio: Allan Chernoff) The findings of new studies of the treatment of patients with advanced colon cancer with the experimental drug Erbitux examined; details given of the Erbitux test results. [American Society of Clinical Oncology president Dr. Paul BUNN- says the trials confirm the drug helps patients.] [May 2001, ImClone Systems CEO Sam WAKSAL- says we feel confident in the drug.] [Cancer patient Rachel HIGHTOWER- says the process of getting drugs that help should be expedited.] The FDA's original decision not to fast track Erbitux & the resulting insider trading scandal at ImClone noted. [American Cancer Society deputy chief medical officer Dr. Len LICHTFELD- cites the lessons about drug research.] The question of whether charges will be brought against Martha Stewart discussed.
- Brown, Aaron;
- Chernoff, Allan
Note to sponsor members: The Vanderbilt Television News Archive video player requires a modern operating system and browser to work properly. If you are experiencing playback problems, check the minimum requirements and adjust your setup accordingly. After adjustments, if you continue to experience problems, please contact us.
Welcome! Above is the abstract of the item that you're interested in viewing from the Vanderbilt Television News Archive's collection. You have three options if you'd like to view this item:
- You may request a loan of this video by registering on our website and placing an order.
- You may visit the Television News Archive on the Vanderbilt campus to view on-site from the Archive's collection.
- If you are associated with a college or university, you may ask your library if they would like to become a sponsor, which would give students and faculty at your institution the ability to view items from our collection.
If you believe that you are associated with a sponsoring college or university and have received this message in error, please let us know.